Developer docs
API playgroundTry for free, no card

Search company profiles

Memphis

Full company profile

uuid003l6bt

Namestring
Memphis
Legal namestring
Memphis Company for Pharmaceuticals and Chemical Industries
Websiteurl
memphis.com.eg
Company typeenum
Private
Founded yearint
1940
Descriptiontext

Memphis Pharmaceuticals & Chemical Industries is an Egyptian pharmaceutical manufacturer established in 1940, headquartered at 8 El Sawah Street, El Amiriya, Cairo, and operating as a subsidiary of the state-owned Egyptian Holding Company for Pharmaceuticals. The company is publicly listed on the Egyptian Exchange under ticker MPCI and employs more than 1,200 staff across five domestic offices, with distribution extending through international agents to 10+ countries in the Middle East and Africa.

The company manufactures 145+ products across 15 GMP-compliant production lines, spanning a broad therapeutic portfolio in human health — antibiotics (Garamycin, Levoflox, Azithroheal, Cipro), NSAIDs and analgesics (Ibufen, Celecox, Cetamol), corticosteroids (Betason, Dexamethasone, Diprosone), gastrointestinal and cardiovascular agents, antihistamines, vitamins and mineral supplements, dermatologicals, and respiratory products — alongside a veterinary line covering anti-coccidiosis, anthelmintics, tetracyclines, and lincomycin-spectinomycin combinations. Manufacturing is supported by an internal R&D center and pipeline, with operations subject to periodic surveillance by international and local health authorities.

Memphis generates revenue through one-time sale of pharmaceutical products distributed directly to Egyptian healthcare providers, pharmacies, and patients via its captive network of scientific centers and sales offices, with international sales routed through agents in MEA export markets. The business is sales-led with no disclosed direct-to-consumer pricing. In FY 2024-2025 the company reported sales of EGP 1.5 billion (versus EGP 871.9 million prior year) and net profit of EGP 504.92 million, a 164% year-on-year increase, while nine-month figures ending March 2025 showed revenue growth of 65.1% YoY to EGP 1.097 billion and a 46.2% gross margin.

Short descriptiontext

Memphis Pharmaceuticals & Chemical Industries is a Cairo-based, state-owned Egyptian pharmaceutical manufacturer founded in 1940, producing 145+ GMP-compliant human and veterinary medicines across 15 production lines for domestic pharmacies and clinics, with exports to 10+ Middle East and African countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCairo, Egypt
HQ citystring
Cairo
HQ countrystring
Egypt
HQ regionstring
Africa
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, human pharmaceuticals, veterinary medicines, generic drug production, antibiotic formulations
Industry2 codes
PRIMARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
SECONDARYHLAMAIAC
Veterinary Vaccine & Biologics Distributors
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sale of pharmaceutical products for human and animal health across multiple therapeutic categories including antibiotics, anti-inflammatory, cardiovascular, vitamins, and more. Revenue generated from domestic Egyptian market and exports to Middle East and Africa.

memphis.com.eg
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Memphis manufactures and distributes human and veterinary pharmaceutical products across multiple therapeutic categories, including antibiotics, anti-inflammatory, cardiovascular, dermatological, and vitamin formulations. It operates 15 production lines producing more than 145 products from its Cairo base, supplying pharmacies, hospitals, clinics, veterinarians, and government health agencies across Egypt and export markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 164% year-on-year profit increase in fiscal year 2024-2025
+2 more records
Product overview1 text field

Memphis Pharmaceuticals and Chemical Industries is an Egyptian pharmaceutical company established in 1940, operating as a subsidiary of the Egyptian Holding Company for Pharmaceuticals. The company manufactures a comprehensive portfolio of human health products and animal health (veterinary) products. Human products include antibiotics (Garamycin, Levoflox, Clarimycin, Azithroheal, Cipro, Noracin), NSAIDs and analgesics (Ibufen, Celecox, Indacin, Cetamol), corticosteroids (Betason, Dexamethasone, F-Corten, Diprosone, Diprosalic), gastrointestinal medications (Famotin, Omepral, Spasmocin, Detrusan, Purgaton), cardiovascular medications (Irbetan, Edemex, Vasorin), antihistamines (Fexodine, Zylofen, Pirafene, Coldact), vitamins and supplements (Trivarol, Devarol-S, Cevarol, Folic Acid, Magnisol, Calcionat), dermatologicals (Ultra-Medanin, Miconol, Beclozone, Memphis Carbamide), and other therapeutic categories. Veterinary products include antibiotics, anti-coccidiosis, anthelmintics, and analgesics. The company operates 15 production lines across its facilities in Cairo, Egypt.

Product and service6 records
1Antibiotic pharmaceuticals
CategoryHuman pharmaceuticals — anti-infectives
Description

Antibiotic formulations produced by Memphis for human healthcare use, supplied to pharmacies, hospitals, clinics, and government health agencies across Egypt and export markets.

2Anti-inflammatory pharmaceuticals
CategoryHuman pharmaceuticals — anti-inflammatory and analgesics
Description

Anti-inflammatory drug formulations manufactured for the treatment of pain and inflammation, supplied to institutional healthcare buyers in Egypt and export markets.

3Cardiovascular pharmaceuticals
CategoryHuman pharmaceuticals — cardiovascular
Description

Cardiovascular drug formulations manufactured for patients with heart and circulatory conditions, supplied to pharmacies, hospitals, and government health agencies.

4Vitamin and nutritional supplements
CategoryHuman pharmaceuticals — vitamins and nutrition
Description

Vitamin and nutritional supplement formulations manufactured by Memphis for human health maintenance, supplied to pharmacies and healthcare institutions.

5Dermatological pharmaceuticals
CategoryHuman pharmaceuticals — dermatology
Description

Dermatological drug formulations manufactured for the treatment of skin conditions, supplied to pharmacies, hospitals, and dermatology clinics.

6Veterinary medicines
CategoryVeterinary pharmaceuticals
Description

Veterinary pharmaceutical formulations produced by Memphis for the treatment of animal diseases, supplied to veterinarians, livestock operations, and animal health distributors.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Egyptian Holding Company for Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parent company and subsidiary relationship. Memphis Pharmaceuticals is a subsidiary of the Egyptian Holding Company for Pharmaceuticals, part of the Ministry of Public Business Sector's strategy to revive and develop assets of affiliated companies.

memphis.com.eg
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

MENA-origin, London-listed multinational generics and specialty pharmaceutical manufacturer with significantly larger scale and broader international footprint; a regional incumbent peer operating in the same therapeutic categories with much deeper market reach.

TypeBroad incumbent
Description

India-based global generic pharmaceutical manufacturer with deep presence across emerging markets including Africa; competes with Memphis in respiratory, antibiotics, and OTC categories, particularly in African export markets.

TypeBroad incumbent
Description

Largest global animal health company; competes with Memphis in veterinary pharmaceuticals across MENA/Africa markets, though at significantly higher scale and broader product range.

TypeDirect peer
Description

Global veterinary pharmaceutical company specializing in animal health products including antibiotics, parasiticides, and anti-coccidials; directly comparable to Memphis's veterinary segment (anthelmintics, anti-coccidiosis, tetracyclines) on product and customer overlap.

TypeDirect peer
Description

Egyptian pharmaceutical manufacturer and fellow subsidiary of Egyptian Holding Company for Pharmaceuticals, making it a state-owned peer with directly comparable product portfolio, manufacturing footprint, and GTM in the Egyptian market.

TypeBroad incumbent
Description

Large Indian generic manufacturer with significant African and emerging-market distribution; competitive in the same generic therapeutic categories where Memphis operates (antibiotics, anti-infectives, vitamins).

TypeDirect peer
Description

Egyptian-headquartered pharmaceutical manufacturer with broad generic and specialty pharma portfolio across human and animal health; the closest direct regional peer serving the same MENA/Africa markets with overlapping product categories.

TypeBroad incumbent
Description

Global multinational pharmaceutical major with broad antibiotics, vaccines, and consumer health portfolios; competes with Memphis in several therapeutic categories across MENA/Africa, particularly in regulated tenders and branded generics.

TypeDirect peer
Description

Egyptian pharmaceutical manufacturer producing generics across multiple therapeutic categories with regional distribution; comparable in scale, product mix, and Egyptian/MENA market positioning.

TypeDirect peer
Description

One of the largest Egyptian pharmaceutical manufacturers with a broad generic portfolio spanning human therapeutics and significant MENA/Africa distribution; comparable in scale, product breadth, and export orientation to Memphis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Memphis

Pharmaceutical Manufacturingmemphis.com.eg

Memphis Pharmaceuticals & Chemical Industries is a Cairo-based, state-owned Egyptian pharmaceutical manufacturer founded in 1940, producing 145+ GMP-compliant human and veterinary medicines across 15 production lines for domestic pharmacies and clinics, with exports to 10+ Middle East and African countries.

What Memphis does

Memphis Pharmaceuticals & Chemical Industries is an Egyptian pharmaceutical manufacturer established in 1940, headquartered at 8 El Sawah Street, El Amiriya, Cairo, and operating as a subsidiary of the state-owned Egyptian Holding Company for Pharmaceuticals. The company is publicly listed on the Egyptian Exchange under ticker MPCI and employs more than 1,200 staff across five domestic offices, with distribution extending through international agents to 10+ countries in the Middle East and Africa.

The company manufactures 145+ products across 15 GMP-compliant production lines, spanning a broad therapeutic portfolio in human health — antibiotics (Garamycin, Levoflox, Azithroheal, Cipro), NSAIDs and analgesics (Ibufen, Celecox, Cetamol), corticosteroids (Betason, Dexamethasone, Diprosone), gastrointestinal and cardiovascular agents, antihistamines, vitamins and mineral supplements, dermatologicals, and respiratory products — alongside a veterinary line covering anti-coccidiosis, anthelmintics, tetracyclines, and lincomycin-spectinomycin combinations. Manufacturing is supported by an internal R&D center and pipeline, with operations subject to periodic surveillance by international and local health authorities.

Memphis generates revenue through one-time sale of pharmaceutical products distributed directly to Egyptian healthcare providers, pharmacies, and patients via its captive network of scientific centers and sales offices, with international sales routed through agents in MEA export markets. The business is sales-led with no disclosed direct-to-consumer pricing. In FY 2024-2025 the company reported sales of EGP 1.5 billion (versus EGP 871.9 million prior year) and net profit of EGP 504.92 million, a 164% year-on-year increase, while nine-month figures ending March 2025 showed revenue growth of 65.1% YoY to EGP 1.097 billion and a 46.2% gross margin.

Memphis firmographics

Firmographics
Name
Memphis
Legal name
Memphis Company for Pharmaceuticals and Chemical Industries
Website
https://memphis.com.eg
Company type
Private
Founded year
1940
Operating status
Operating
Headcount range
101–250 employees
Short description
Memphis Pharmaceuticals & Chemical Industries is a Cairo-based, state-owned Egyptian pharmaceutical manufacturer founded in 1940, producing 145+ GMP-compliant human and veterinary medicines across 15 production lines for domestic pharmacies and clinics, with exports to 10+ Middle East and African countries.
Ownership category
akta.pro rank

Memphis industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
SECONDARYHLAMAIAC
Veterinary Vaccine & Biologics Distributors
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)

Keywords

  • Pharmaceutical manufacturing
  • Human pharmaceuticals
  • Veterinary medicines
  • Generic drug production
  • Antibiotic formulations

Where Memphis is headquartered

Location

Headquarters

HQ city
Cairo
HQ country
Egypt
HQ region
Africa

Offices3 records

Markets served

Memphis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Sale of pharmaceutical products for human and animal health across multiple therapeutic categories including antibiotics, anti-inflammatory, cardiovascular, vitamins, and more. Revenue generated from domestic Egyptian market and exports to Middle East and Africa.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Memphis product offering

Product offering

Core offering

Memphis manufactures and distributes human and veterinary pharmaceutical products across multiple therapeutic categories, including antibiotics, anti-inflammatory, cardiovascular, dermatological, and vitamin formulations. It operates 15 production lines producing more than 145 products from its Cairo base, supplying pharmacies, hospitals, clinics, veterinarians, and government health agencies across Egypt and export markets.

Product overview

Memphis Pharmaceuticals and Chemical Industries is an Egyptian pharmaceutical company established in 1940, operating as a subsidiary of the Egyptian Holding Company for Pharmaceuticals. The company manufactures a comprehensive portfolio of human health products and animal health (veterinary) products. Human products include antibiotics (Garamycin, Levoflox, Clarimycin, Azithroheal, Cipro, Noracin), NSAIDs and analgesics (Ibufen, Celecox, Indacin, Cetamol), corticosteroids (Betason, Dexamethasone, F-Corten, Diprosone, Diprosalic), gastrointestinal medications (Famotin, Omepral, Spasmocin, Detrusan, Purgaton), cardiovascular medications (Irbetan, Edemex, Vasorin), antihistamines (Fexodine, Zylofen, Pirafene, Coldact), vitamins and supplements (Trivarol, Devarol-S, Cevarol, Folic Acid, Magnisol, Calcionat), dermatologicals (Ultra-Medanin, Miconol, Beclozone, Memphis Carbamide), and other therapeutic categories. Veterinary products include antibiotics, anti-coccidiosis, anthelmintics, and analgesics. The company operates 15 production lines across its facilities in Cairo, Egypt.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antibiotic pharmaceuticals Antibiotic formulations produced by Memphis for human healthcare use, supplied to pharmacies, hospitals, clinics, and government health agencies across Egypt and export markets.
  • Anti-inflammatory pharmaceuticals Anti-inflammatory drug formulations manufactured for the treatment of pain and inflammation, supplied to institutional healthcare buyers in Egypt and export markets.
  • Cardiovascular pharmaceuticals Cardiovascular drug formulations manufactured for patients with heart and circulatory conditions, supplied to pharmacies, hospitals, and government health agencies.
  • Vitamin and nutritional supplements Vitamin and nutritional supplement formulations manufactured by Memphis for human health maintenance, supplied to pharmacies and healthcare institutions.
  • Dermatological pharmaceuticals Dermatological drug formulations manufactured for the treatment of skin conditions, supplied to pharmacies, hospitals, and dermatology clinics.
  • Veterinary medicines Veterinary pharmaceutical formulations produced by Memphis for the treatment of animal diseases, supplied to veterinarians, livestock operations, and animal health distributors.

Quantifiable outcome

  • 164% year-on-year profit increase in fiscal year 2024-2025
  • +2 more outcomes

Companies that use Memphis

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Memphis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Memphis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Egyptian Holding Company for PharmaceuticalscoreStrategic or Co-development PartnerParent company and subsidiary relationship. Memphis Pharmaceuticals is a subsidiary of the Egyptian Holding Company for Pharmaceuticals, part of the Ministry of Public Business Sector's strategy to revive and develop assets of affiliated companies.

Scale indicators13 records

Recent moves6 records

Expansion highlights4 records

Memphis competitors and assessment

Company assessment

Broad incumbents

  • Hikma Pharmaceuticals: MENA-origin, London-listed multinational generics and specialty pharmaceutical manufacturer with significantly larger scale and broader international footprint; a regional incumbent peer operating in the same therapeutic categories with much deeper market reach.
  • Cipla: India-based global generic pharmaceutical manufacturer with deep presence across emerging markets including Africa; competes with Memphis in respiratory, antibiotics, and OTC categories, particularly in African export markets.
  • Zoetis: Largest global animal health company; competes with Memphis in veterinary pharmaceuticals across MENA/Africa markets, though at significantly higher scale and broader product range.
  • Aurobindo Pharma: Large Indian generic manufacturer with significant African and emerging-market distribution; competitive in the same generic therapeutic categories where Memphis operates (antibiotics, anti-infectives, vitamins).
  • GSK: Global multinational pharmaceutical major with broad antibiotics, vaccines, and consumer health portfolios; competes with Memphis in several therapeutic categories across MENA/Africa, particularly in regulated tenders and branded generics.

Direct peers

  • Vetoquinol: Global veterinary pharmaceutical company specializing in animal health products including antibiotics, parasiticides, and anti-coccidials; directly comparable to Memphis's veterinary segment (anthelmintics, anti-coccidiosis, tetracyclines) on product and customer overlap.
  • EIPICO (Egyptian International Pharmaceutical Industries Company): Egyptian pharmaceutical manufacturer and fellow subsidiary of Egyptian Holding Company for Pharmaceuticals, making it a state-owned peer with directly comparable product portfolio, manufacturing footprint, and GTM in the Egyptian market.
  • Eva Pharma: Egyptian-headquartered pharmaceutical manufacturer with broad generic and specialty pharma portfolio across human and animal health; the closest direct regional peer serving the same MENA/Africa markets with overlapping product categories.
  • Amriya Pharmaceutical Industries: Egyptian pharmaceutical manufacturer producing generics across multiple therapeutic categories with regional distribution; comparable in scale, product mix, and Egyptian/MENA market positioning.
  • Pharco Pharmaceuticals: One of the largest Egyptian pharmaceutical manufacturers with a broad generic portfolio spanning human therapeutics and significant MENA/Africa distribution; comparable in scale, product breadth, and export orientation to Memphis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Memphis social profiles

Digital presence

Memphis compliance and trust

Trust signal

Compliance1 record

Memphis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Memphis leadership team

Management profile

Number of profiles

Profiles1 record

Memphis funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Memphis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Memphis

What does Memphis do?

Memphis manufactures and distributes human and veterinary pharmaceutical products across multiple therapeutic categories, including antibiotics, anti-inflammatory, cardiovascular, dermatological, and vitamin formulations. It operates 15 production lines producing more than 145 products from its Cairo base, supplying pharmacies, hospitals, clinics, veterinarians, and government health agencies across Egypt and export markets.

Is Memphis a public or private company?

Memphis is a private company. It is classified as state government owned and is currently operating.

When was Memphis founded?

Memphis was founded in 1940. It employs 101 to 250 people.

Where is Memphis based?

Memphis is headquartered in Cairo, Egypt, in the Africa region.

How does Memphis make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Memphis's main competitors?

Broad incumbents on record are Hikma Pharmaceuticals, Cipla, Zoetis, Aurobindo Pharma and GSK. Direct peers are Vetoquinol, EIPICO (Egyptian International Pharmaceutical Industries Company), Eva Pharma, Amriya Pharmaceutical Industries and Pharco Pharmaceuticals.

Does Memphis have an API?

No public API is recorded for Memphis.

What industry is Memphis in?

Memphis's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is AFAEANAK, Veterinary Pharmacy, Vaccine & Biologics Services, with a secondary code of HLAMAIAC, Veterinary Vaccine & Biologics Distributors. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ZawyaEgypt: Memphis Pharmaceutical’s profits decline 4%YoY in FY 2025/26Memphis Pharmaceutical and Chemical Industries reported a 4% year-on-year decline in net profits after tax for fiscal year 2025/2026, with profits falling to EGP 483.868 million from EGP 505.280 million in the prior year. Despite the profit contraction, the company's revenues grew 13% to EGP 1.705 billion from EGP 1.507 billion. Memphis is one of the oldest pharmaceutical and chemical companies in the Middle East, having operated in the market since 1940.Mubasher Info'Osoul Investments' increases its stake in Memphis Pharmaceuticals by more than 6 million poundsAssets Investment Company bought 27,450 shares in Memphis Pharmaceuticals for 6.093 million Egyptian pounds, averaging 222 EGP per share. The purchase raised its stake from 1.69% to 1.89%, and its related group's ownership rose to 5.07% of the company's capital.YahooMemphis AD says this season will be 'better barometer' of Penny Hardaway as coachMemphis Athletic Director Ed Scott said in a June 3 radio interview that he has not discussed a contract extension with basketball coach Penny Hardaway and wants him to focus on the upcoming season, which he believes will serve as a better measure of Hardaway's coaching abilities. Hardaway is entering his ninth season with two years remaining on his deal ($2.7M for 2026-27, $2.8M for 2027-28) after a disappointing 13-19 season. Scott publicly backed Hardaway, citing full institutional support including revenue sharing, a new coaching staff, roster overhaul with 14 players, and access to behavioral assessment company Profile.The Guardian‘Major labels are trying to scoop up everything’: the chaotic future for indie music companies – and why vinyl isn’t workingMultiple independent record labels including Sub Pop, Secretly Group, Rhythm Section, Hyperdub, Melodic, and Memphis Industries are celebrating milestone anniversaries while navigating escalating challenges such as tripled artist advances driven by major label competition, spiraling production and touring costs, and the misleading perception of vinyl as a profit driver when streaming actually accounts for 80% of profits for some labels. Executives and label heads interviewed for the article describe a bifurcated industry where only superstar-level or legacy catalogue artists can achieve economic sustainability, with mid-tier artists increasingly squeezed. Labels are compensating by diversifying into merchandise, label management, sync licensing deals, and artist management to offset the precarity of core record sales.YahooDayton women's basketball adds Memphis transfer, new assistant coachDayton Flyers women's basketball added Cori Allen, a 5-foot-10 junior guard transfer from Memphis, who averaged 6.5 points, 4.4 rebounds, and 2.6 assists per game last season and has one season of eligibility remaining. The program also hired Brittany Parker as an assistant coach and recruiting coordinator, joining from Virginia Commonwealth, while also distributing team awards including MVP to Nayo Lear. Sophomore guard Kamryn Grant entered the transfer portal in early April after averaging 1.0 point over two seasons at Dayton.KoreatimesItalian design master urges Korean designers to focus on emotion, sustainabilityItalian architect and designer Michele De Lucchi visited Seoul as the official design ambassador for the 10th edition of Italian Design Day, delivering a masterclass titled 'Life is a Dance' at High Street Italia in southern Seoul on Tuesday. The 75-year-old design maestro, known for creating the iconic Tolomeo lamp for Artemide and his work with Memphis group, advised Korean designers to focus on emotional and social needs alongside functionality, particularly addressing an aging population and environmental sustainability. The Italian Design Day program continues through March 23 with roundtable discussions featuring Italian brands and a masterclass with Samsung Electronics' chief design officer Mauro Porcini.YahooMemphis basketball fires former Lady Vol as head coachThe University of Memphis relieved Alex Simmons of her duties as women's basketball head coach after three seasons, during which she compiled a 30-61 overall record (18-36 AAC). Senior Vice President and Director of Intercollegiate Athletics Ed Scott announced the decision following a comprehensive evaluation of the program, stating the university believes this is the right time for a leadership change. Simmons, a former Tennessee Lady Vols player, previously earned Big South Coach of the Year honors in 2023 at Gardner-Webb before joining Memphis in 2018.YahooWichita State vs Memphis Prediction, Picks & Odds for Tonight's College Basketball GameThis article provides betting predictions and picks for the college basketball game between Wichita State and Memphis on February 26, 2026 at FedExForum. The analysis covers betting odds, player props, and game trends, with key recommendations including the Under 147 total and specific player props for Karon Boyd and Julius Thedford. The piece notes Memphis is on a four-game losing streak and discusses factors that could affect the betting line.YahooIn Cortez Braham case, NCAA threatens 'rule of restitution' against MemphisThe NCAA is continuing to litigate an eligibility lawsuit filed by Cortez Braham, a Memphis football player, related to a preliminary injunction affecting his eligibility in 2025. The NCAA argued that the lawsuit's issue was not moot and that they could enforce a 'rule of restitution' against Memphis, which could include vacating records, stripping victories, or imposing penalties. The legal case impacts Memphis and Braham's eligibility and could lead to penalties against Memphis if the NCAA prevails.Gadgets 360US Zoo Offers To Name Animal Poop After Your Ex This Valentine's DayThe Maryland Zoo announced its second annual Dollars for Dung fundraiser, offering participants the chance to name a pile of animal dung after their ex for a $5 donation supporting conservation efforts. Last year's campaign at the zoo raised nearly $10,000 from donors across over 30 countries. The Memphis Zoo in Tennessee previously ran a similar program offering elephant poop videos for a $10 donation.